 
Colon Study

DLBCL Study

Leukemia Study



Ordering

Tumor

Normal

DLBCL

FL

ALL

AML

π
_{1}

X_{
i
}<X_{
j
}<X_{
k
}

0.125

0.045

0.362

0

0.340

0

π
_{2}

X_{
i
}<X_{
k
}<X_{
j
}

0.4

0

0.569

0

0

0.04

π
_{3}

X_{
j
}<X_{
i
}<X_{
k
}

0.075

0.864

0.052

0

0.660

0

π
_{4}

X_{
j
}<X_{
k
}<X_{
i
}

0

0.091

0

0.684

0

0.08

π
_{5}

X_{
k
}<X_{
i
}<X_{
j
}

0.4

0

0.017

0.053

0

0.76

π
_{6}

X_{
k
}<X_{
j
}<X_{
i
}

0

0

0

0.263

0

0.12

 
Prostate1 Study

Lung Study

GCM Study


Ordering

Cancer

Normal

MPM

ADCA

Tumor

Normal

π
_{1}

X_{
i
}<X_{
j
}<X_{
k
}

0.04

0

0

0.12

0.8

0.222

π
_{2}

X_{
i
}<X_{
k
}<X_{
j
}

0.1

0

0

0.827

0.113

0.5

π
_{3}

X_{
k
}<X_{
i
}<X_{
k
}

0.02

0.115

0.258

0.007

0.079

0.022

π
_{4}

X_{
j
}<X_{
k
}<X_{
i
}

0.06

0.807

0.742

0

0

0.044

π
_{5}

X_{
k
}<X_{
i
}<X_{
j
}

0.5

0.019

0

0.02

0.008

0.179

π
_{6}

X_{
k
}<X_{
j
}<X_{
i
}

0.28

0.059

0

0.027

0

0.033

 Each portion of the corresponds to one study with two phenotypes. For each study and each phenotype, the table shows the relative frequencies of the six possible orderings among the expression values of the topscoring triple for the samples in the study. The gene triple (g_{
i
}, g_{
j
}, g_{
k
}) for each study is given in Table 4